Special Issue "Free or Nanoformulated Forms of Novel Protease Inhibitors for Cancer Therapy"

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".

Deadline for manuscript submissions: closed (31 March 2023) | Viewed by 246

Special Issue Editor

Department of Sciences, University of Basilicata, Basilicata, Italy
Interests: ER stress; apoptosis; autophagy; proteasome inhibition; liver cancer; cell culture; biochemistry; proteomics

Special Issue Information

Dear Colleagues,

I recently accepted the invitation to serve as Guest Editor for a new Special Issue of the journal Pharmaceutics on the subject of “Free or Nanoformulated Forms of Novel Protease Inhibitors for Cancer Therapy”. Many studies indicate that intracellular proteases often participate in tumor growth and progression, being involved in important biological processes such as immune and inflammatory responses, angiogenesis, proliferation, epithelial-to-mesenchymal transition (EMT) and many others. Among the anticancer strategies, the antagonization of protease activity with increasingly effective molecules is certainly an encouraging therapeutic approach, especially if formulated in nanoparticle-based delivery systems that can increase bioavailability and circulation time and allow for accumulation—specifically in tumor tissues.

This Special Issue aims to establish a collection of papers to provide cutting-edge insight into all interested in this area of research. We welcome papers in the form of full research papers or focused reviews on some aspects of the theme. If you are interested in contributing or have any questions, please do not hesitate to let us know or contact the Assistant Editor.

I look forward to receiving your contributions.

Dr. Maria Francesca Armentano
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • human proteases
  • proteases inhibitors
  • cancer treatment
  • ubiquitin–proteasome pathway inhibitors
  • apoptosis
  • nanoscale drug-delivery systems
  • lipidic nanoparticles
  • targeting approaches

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop